Genmab and Seattle Genetics (SGI) have entered into an antibody-drug conjugate (ADC) research collaboration, under which Genmab will use SGI’s ADC technology with its HuMax-TF antibody targeting the Tissue Factor antigen in solid tumors. SGI received an undisclosed payment and has the right to exercise a co-development option for any resulting ADC products at the end of Phase I development.

Genmab is responsible for research, manufacturing, and development through Phase I trials. Seattle Genetics will receive research support payments for assistance provided to Genmab. If SGI exercises it option at the end of Phase I, the companies would co-develop and share future costs and profits for the product. If not, Genmab would pay fees, milestones and royalties on sales.

“ADC technology represents the next promising wave of cancer therapeutics, combining the best characteristics of antibodies and chemotherapy into one,” said Jan van de Winkel, Ph.D., chief executive officer of Genmab. “We are pleased to enter this collaboration with Seattle Genetics which gives us access to this innovative technology for HuMax-TF.”